{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:33:10Z","timestamp":1793226790947,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI183687"],"award-info":[{"award-number":["AI183687"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI176245"],"award-info":[{"award-number":["AI176245"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.dmd.2025.100158","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:48:49Z","timestamp":1757375329000},"page":"100158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanistic insights into human carboxylesterase 2 (CES2) inhibition by the CES1 prodrug substrate remdesivir"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1507-5488","authenticated-orcid":false,"given":"Abhinav","family":"Pentyala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-8035","authenticated-orcid":false,"given":"Sylvie E.","family":"Kandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-2263","authenticated-orcid":false,"given":"Jed N.","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dmd.2025.100158_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00228-016-2170-6","article-title":"Hospitalizations due to preventable adverse reactions-a systematic review","volume":"73","author":"Patel","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100158_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14740338.2018.1491547","article-title":"The economic burden of preventable adverse drug reactions: a systematic review of observational studies","volume":"17","author":"Formica","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.dmd.2025.100158_bib4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","article-title":"The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600 000 elderly patients from the Swedish prescribed drug register","volume":"30","author":"Johnell","year":"2007","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.dmd.2025.100158_bib5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00228-012-1309-3","article-title":"Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study","volume":"68","author":"Obreli-Neto","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00228-015-1974-0","article-title":"Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features","volume":"72","author":"Pedr\u00f3s","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100158_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.923939","article-title":"Adverse drug reactions and correlations with drug-drug interactions: a retrospective study of reports from 2011 to 2020","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bcp.14139","article-title":"Preventable adverse drug events: Descriptive epidemiology","volume":"86","author":"Woo","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100158_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055551","article-title":"Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions","volume":"12","author":"Osanlou","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.dmd.2025.100158_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DHPS.S126336","article-title":"Potential drug-drug interactions in inpatients treated at the Internal Medicine ward of Tikur Anbessa Specialized Hospital","volume":"9","author":"Tesfaye","year":"2017","journal-title":"Drug Healthc Patient Saf"},{"issue":"1","key":"10.1016\/j.dmd.2025.100158_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3892\/or.2021.8231","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with poly (ADP-ribose) polymerase inhibitors (Review)","volume":"47","author":"Zhao","year":"2022","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100158_bib13","series-title":"Paxlovid (nirmatrelvir)","year":"2025"},{"key":"10.1016\/j.dmd.2025.100158_bib14","series-title":"Veklury (remdesivir)","year":"2025"},{"key":"10.1016\/j.dmd.2025.100158_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci Rep"},{"issue":"396","key":"10.1016\/j.dmd.2025.100158_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.dmd.2025.100158_bib17","series-title":"Letter of authorization for emergency use of Lagevrio (molnupiravir)","year":"2023"},{"issue":"24","key":"10.1016\/j.dmd.2025.100158_bib18","doi-asserted-by":"crossref","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100158_bib19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.121.000801","article-title":"Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans","volume":"50","author":"Eng","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2025.100158_bib20","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/dmd.122.000918","article-title":"The COVID-19 oral drug molnupiravir is a CES2 substrate: potential drug-drug interactions and impact of CES2 genetic polymorphism in vitro","volume":"50","author":"Shen","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100158_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109744","article-title":"Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans","volume":"351","author":"Zhang","year":"2022","journal-title":"Chem Biol Interact"},{"issue":"10","key":"10.1016\/j.dmd.2025.100158_bib22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2174\/092986609789071324","article-title":"Human carboxylesterases: an update on CES1, CES2 and CES3","volume":"16","author":"Sanghani","year":"2009","journal-title":"Protein Pept Lett"},{"issue":"1","key":"10.1016\/j.dmd.2025.100158_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bcp.2010.09.001","article-title":"Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11","volume":"81","author":"Hatfield","year":"2011","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100158_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/bbrc.1997.6413","article-title":"Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver","volume":"233","author":"Schwer","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0003-9861(74)90304-X","article-title":"Human liver carboxylesterase. Purification and molecular properties","volume":"165","author":"Junge","year":"1974","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.dmd.2025.100158_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0009-2797(99)00057-5","article-title":"Different role of carboxylesterases in toxicity and tolerance to paraoxon and DFP","volume":"119\u2013120","author":"Dettbarn","year":"1999","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.dmd.2025.100158_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.abb.2005.11.005","article-title":"Characterization of pyrethroid hydrolysis by the human liver carboxylesterases hCE-1 and hCE-2","volume":"445","author":"Nishi","year":"2006","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.dmd.2025.100158_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/hep4.1487","article-title":"Hepatocyte-specific expression of human carboxylesterase 1 attenuates diet-induced steatohepatitis and hyperlipidemia in mice","volume":"4","author":"Xu","year":"2020","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib29","doi-asserted-by":"crossref","first-page":"G166","DOI":"10.1152\/ajpgi.00315.2020","article-title":"Hepatocyte-specific expression of human carboxylesterase 2 attenuates nonalcoholic steatohepatitis in mice","volume":"320","author":"Xu","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.dmd.2025.100158_bib30","series-title":"Encyclopedia of Drug Metabolism and Interactions","first-page":"1","article-title":"Carboxylesterases","author":"Yan","year":"2011"},{"issue":"8","key":"10.1016\/j.dmd.2025.100158_bib31","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.116.070763","article-title":"Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006\u20132015","volume":"44","author":"Cerny","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/fcp.12643","article-title":"Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions","volume":"35","author":"Shen","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100158_bib33","series-title":"Enzyme Inhibition in Drug Discovery and Development: the Good and the Bad","author":"Lu","year":"2010"},{"issue":"3","key":"10.1016\/j.dmd.2025.100158_bib34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2016.11.025","article-title":"Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil","volume":"66","author":"Shen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dmd.2025.100158_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/B978-0-444-62645-5.00005-5","article-title":"Noncholinesterase protein targets of organophosphorus pesticides","author":"Lockridge","year":"2013","journal-title":"Advances in Molecular Toxicology. Elsevier;"},{"issue":"7","key":"10.1016\/j.dmd.2025.100158_bib36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/cid\/ciaa883","article-title":"Drug-induced liver injury in a patient with coronavirus disease 2019: potential interaction of remdesivir with P-glycoprotein inhibitors","volume":"72","author":"Leegwater","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.dmd.2025.100158_bib37","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s12072-020-10077-3","article-title":"Liver injury in remdesivir-treated COVID-19 patients","volume":"14","author":"Zampino","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dmd.2025.100158_bib38","article-title":"Antiviral use in liver function abnormalities and Covid-19 patients: serial cases","volume":"84","author":"Dewi","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"10.1016\/j.dmd.2025.100158_bib39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.28472","article-title":"Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice","volume":"63","author":"Li","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.dmd.2025.100158_bib40","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.26714","article-title":"Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis","volume":"59","author":"Xu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2025.100158_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115250","article-title":"Emerging role of carboxylesterases in nonalcoholic fatty liver disease","volume":"205","author":"Liu","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.vascn.2007.11.003","article-title":"Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases","volume":"57","author":"Williams","year":"2008","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.dmd.2025.100158_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2018.07.034","article-title":"Esterase activity in porcine and albino rabbit ocular tissues","volume":"123","author":"Heikkinen","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1432-1033.1974.tb03267.x","article-title":"The hydrolysis of p-nitrophenylacetate in water: mechanism and method of measurement","volume":"41","author":"Goren","year":"1974","journal-title":"Eur J Biochem"},{"issue":"8","key":"10.1016\/j.dmd.2025.100158_bib45","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.111.039628","article-title":"Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2","volume":"39","author":"Wang","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2025.100158_bib46","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1124\/dmd.122.000993","article-title":"Activity and expression of carboxylesterases and arylacetamide deacetylase in human ocular tissues","volume":"50","author":"Hammid","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2025.100158_bib47","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1124\/dmd.110.034454","article-title":"In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities","volume":"38","author":"Fukami","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100158_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.419","article-title":"A comprehensive guide for assessing covalent inhibition in enzymatic assays illustrated with kinetic simulations","volume":"2","author":"Mons","year":"2022","journal-title":"Curr Protoc"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"1","key":"10.1016\/j.dmd.2025.100158_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A perspective on the kinetics of covalent and irreversible inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.dmd.2025.100158_bib51","author":"Eleanor"},{"issue":"15","key":"10.1016\/j.dmd.2025.100158_bib53","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.dmd.2025.100158_bib54","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1093\/cid\/ciae512","article-title":"Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dmd.2025.100158_bib55","series-title":"Guideline on the investigation of drug interactions","year":"2012"},{"key":"10.1016\/j.dmd.2025.100158_bib56","series-title":"M12 drug interaction studies","year":"2024"},{"issue":"10","key":"10.1016\/j.dmd.2025.100158_bib57","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/jac\/dkaa239","article-title":"Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19","volume":"75","author":"Tempestilli","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.dmd.2025.100158_bib58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/ph14070655","article-title":"ADME and pharmacokinetic properties of remdesivir: its drug interaction potential","volume":"14","author":"Deb","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.dmd.2025.100158_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/187231208783478407","article-title":"An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes","volume":"2","author":"Berry","year":"2008","journal-title":"Drug Metab Lett"},{"key":"10.1016\/j.dmd.2025.100158_bib60","article-title":"Deciding between one-step and two-step irreversible inhibition mechanisms on the basis of \u201ckobs\u201d data: a statistical approach","author":"Kuzmi\u010d","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.dmd.2025.100158_bib61","series-title":"Annu Reports in Medicinal Chemistry","first-page":"1","article-title":"Kinetic mechanisms of covalent inhibition","author":"McWhirter","year":"2021"},{"key":"10.1016\/j.dmd.2025.100158_bib62","article-title":"Novel inhibitors and activity-based probes targeting serine proteases","volume":"10","author":"Ferguson","year":"2022","journal-title":"Front Chem"},{"issue":"9","key":"10.1016\/j.dmd.2025.100158_bib63","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/febs.16404","article-title":"A guide to enzyme kinetics in early drug discovery","volume":"290","author":"Srinivasan","year":"2023","journal-title":"FEBS Journal"},{"issue":"9","key":"10.1016\/j.dmd.2025.100158_bib64","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bcp.2012.08.017","article-title":"Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597","volume":"84","author":"Crow","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100158_bib65","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nsb790","article-title":"Structural insights into CPT-11 activation by mammalian carboxylesterases","volume":"9","author":"Bencharit","year":"2002","journal-title":"Nat Struct Biol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100158_bib66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1074-5521(03)00071-1","article-title":"Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition","volume":"10","author":"Bencharit","year":"2003","journal-title":"Chem Biol"},{"issue":"13","key":"10.1016\/j.dmd.2025.100158_bib67","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2174\/092986709788186246","article-title":"Irreversible inhibition of serine proteases-design and in vivo activity of diaryl \u03b1-Aminophosphonate derivatives","volume":"16","author":"Sienczyk","year":"2009","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.dmd.2025.100158_bib68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/ph12020086","article-title":"Recent developments in peptidyl diaryl phoshonates as inhibitors and activity-based probes for serine proteases","volume":"12","author":"Ma\u015blanka","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.dmd.2025.100158_bib69","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.biochi.2019.03.005","article-title":"Proteinase 3 phosphonic inhibitors","volume":"166","author":"Grzywa","year":"2019","journal-title":"Biochimie"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:09:58Z","timestamp":1793225398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0090955625091676"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100158","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into human carboxylesterase 2 (CES2) inhibition by the CES1 prodrug substrate remdesivir","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100158"}}